The approval of evolocumab (Repatha) creates competition in the new class of PCSK9 cholesterol-fighting therapies and managed care plans and pharmacy benefit managers are expected to take full ...
Amgen on Friday revealed its PCSK9 drug Repatha (evolocumab) reduced the risk of major adverse cardiovascular events but had no effect on cardiovascular death, mixed results which could spell ...
Repatha, a PCSK9 inhibitor, lowers cholesterol well, especially for those intolerant to statins, but its absolute risk ...
Amgen’s cholesterol-fighter Repatha rolled back atherosclerosis in a new clinical trial, showing that the drug doesn’t just push LDL cholesterol down by impressive margins. But the results might not ...
THOUSAND OAKS, Calif., Jan. 21, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the cholesterol-lowering medication ...
BRUSSELS, BELGIUM — Evolocumab (Repatha, Amgen), one of the proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors, is the first of these agents approved in Europe for the treatment of patients ...
The trial included a total of 968 CAD patients undergoing cardiac catheterization Amgen announced positive topline results from the Phase 3 GLAGOV trial evaluating the effect of Repatha (evolocumab) ...
Amgen Inc.AMGN presented encouraging one-year data from the phase II (OSLER-1) and phase III (OSLER-2) open-label extension studies and phase III YUKAWA-2 study on its PCSK9 inhibitor, Repatha ...
The FDA approved Amgen 's AMGN new cholesterol-lowering medication, Repatha (evolocumab), making it the second PCSK9 inhibitor to gain approval in the U.S. this year. Repatha's approval comes a month ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results